WO2015114163A3 - Zusammensetzung zur prophylaxe oder behandlung von oxidativem stress - Google Patents

Zusammensetzung zur prophylaxe oder behandlung von oxidativem stress Download PDF

Info

Publication number
WO2015114163A3
WO2015114163A3 PCT/EP2015/052201 EP2015052201W WO2015114163A3 WO 2015114163 A3 WO2015114163 A3 WO 2015114163A3 EP 2015052201 W EP2015052201 W EP 2015052201W WO 2015114163 A3 WO2015114163 A3 WO 2015114163A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxidative stress
composition
prophylaxis
treatment
qba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/052201
Other languages
English (en)
French (fr)
Other versions
WO2015114163A2 (de
Inventor
Hermann Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2015114163A2 publication Critical patent/WO2015114163A2/de
Publication of WO2015114163A3 publication Critical patent/WO2015114163A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

Die Erfindung betrifft eine Zusammensetzung zur Prophylaxe oder Behandlung von oxidativem Stress und den aus oxidativem Stress resultierenden Schäden, Erkrankungen und Zuständen, wobei die Zusammensetzung mindestens ein quaternäres Benzophenanthridinalkaloid (QBA) enthält, vorzugsweise ausgewählt aus der Gruppe bestehend aus Sanguinarin, Chelerythrin und deren Salzen.
PCT/EP2015/052201 2014-02-03 2015-02-03 Zusammensetzung zur prophylaxe oder behandlung von oxidativem stress Ceased WO2015114163A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA75/2014A AT515336A1 (de) 2014-02-03 2014-02-03 Vermeidung oxidativer Prozesse und oxidativem Stress
ATA75/2014 2014-02-03

Publications (2)

Publication Number Publication Date
WO2015114163A2 WO2015114163A2 (de) 2015-08-06
WO2015114163A3 true WO2015114163A3 (de) 2015-10-29

Family

ID=52444305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/052201 Ceased WO2015114163A2 (de) 2014-02-03 2015-02-03 Zusammensetzung zur prophylaxe oder behandlung von oxidativem stress

Country Status (2)

Country Link
AT (1) AT515336A1 (de)
WO (1) WO2015114163A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3851116A1 (de) * 2020-01-20 2021-07-21 Phytobiotics Futterzusatzstoffe GmbH Substanzkombination mit isochinolinalkaloiden und kokzidiostatikum oder kokzidioseimpfmittel
IL303943A (en) * 2020-12-24 2023-08-01 Intervet Int Bv Methods for treating mastitis using the antimicrobial orthosomycin compound
CN114231446B (zh) * 2021-11-30 2023-05-05 佛山市孛特碧欧微生物科技有限公司 鼠李糖乳杆菌lrx-01的应用
CN115054942A (zh) * 2022-06-09 2022-09-16 珠海科技学院 一种博落回提取物的制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002021932A2 (de) * 2000-09-15 2002-03-21 Herrmann Roth Futtermittel, futterzusatzmittel und heilmittel gegen darmentzündung
WO2004060402A1 (de) * 2002-12-28 2004-07-22 Gradl-Grams, Marianne Verfahren sowohl als stoff zur spezifischen proliferationsförderung von lymphozytensubpopulationen durch eine kombination eines immunmodulators mit einem nichtwasserlöslichen naturstoff und einem carrier
DE102008010362A1 (de) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
KR20090095740A (ko) * 2008-03-06 2009-09-10 경희대학교 산학협력단 항염증 및 항통증 작용을 갖는 관절염 예방 및 개선을 위한건강기능식품
WO2011104412A2 (es) * 2010-02-25 2011-09-01 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer
WO2011127496A1 (de) * 2010-04-15 2011-10-20 Klaus Neufeld Tierfutterzusatz mit antimikrobieller und leistungsfördernder wirkung
CN103374008A (zh) * 2012-04-16 2013-10-30 上海壹志医药科技有限公司 白屈菜红碱衍生物的盐

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403873B (de) * 1992-02-21 1998-06-25 Neufeld Klaus Dr Tierfutter zur leistungssteigerung
KR100503925B1 (ko) * 2001-07-31 2005-07-27 김종덕 항산화성을 갖는, 장내 세균 성장촉진용 조성물
ITMI20080038A1 (it) * 2008-01-11 2009-07-12 Indena Spa Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002021932A2 (de) * 2000-09-15 2002-03-21 Herrmann Roth Futtermittel, futterzusatzmittel und heilmittel gegen darmentzündung
WO2004060402A1 (de) * 2002-12-28 2004-07-22 Gradl-Grams, Marianne Verfahren sowohl als stoff zur spezifischen proliferationsförderung von lymphozytensubpopulationen durch eine kombination eines immunmodulators mit einem nichtwasserlöslichen naturstoff und einem carrier
DE102008010362A1 (de) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
KR20090095740A (ko) * 2008-03-06 2009-09-10 경희대학교 산학협력단 항염증 및 항통증 작용을 갖는 관절염 예방 및 개선을 위한건강기능식품
WO2011104412A2 (es) * 2010-02-25 2011-09-01 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer
WO2011127496A1 (de) * 2010-04-15 2011-10-20 Klaus Neufeld Tierfutterzusatz mit antimikrobieller und leistungsfördernder wirkung
CN103374008A (zh) * 2012-04-16 2013-10-30 上海壹志医药科技有限公司 白屈菜红碱衍生物的盐

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BERTOGLIO J C ET AL: "Management of gastrointestinal mucositis due to cancer therapies in pediatric patients: Results of a case series with SAMITAL(R)", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, vol. 8, no. 11, 1 November 2012 (2012-11-01), pages 1481 - 1486, XP009166546, ISSN: 1479-6694, DOI: 10.2217/FON.12.132 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 25 June 2003 (2003-06-25), HAN YA-LING ET AL: "Protein kinase C and protein tyrosine kinase mediate lipopolysaccharide- and cytokine-induced nitric oxide formation in vascular smooth muscle cells of rats.", XP002736665, Database accession no. PREV200300553178 *
E. L. BRADSHAW ET AL: "Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C", AJP: CELL PHYSIOLOGY, vol. 291, no. 6, 1 December 2006 (2006-12-01), pages C1271 - C1278, XP055200011, ISSN: 0363-6143, DOI: 10.1152/ajpcell.00211.2006 *
HASEEB AHSAN ET AL: "Protective Effect of Sanguinarine on Ultraviolet B-mediated Damages in SKH-1 Hairless Mouse Skin: Implications for Prevention of Skin Cancer", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 83, no. 4, 29 July 2007 (2007-07-29), pages 986 - 993, XP055200100, ISSN: 0031-8655, DOI: 10.1111/j.1751-1097.2007.00156.x *
HIROAKI ITO ET AL: "A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease*", GASTROENTEROLOGY, vol. 126, no. 4, 1 April 2004 (2004-04-01), pages 989 - 996, XP055172591, ISSN: 0016-5085, DOI: 10.1053/j.gastro.2004.01.012 *
J JANKOWSKI ET AL: "Gastrointestinal tract and metabolic response of broilers to diets with the Macleaya cordata alkaloid extract Verdauungstrakt und Stoffwechselreaktion von Broilern bei Verfütterung von Rationen mit dem Alkaloidextrakt Sanguinarin aus Macleaya cordata", 1 January 2009 (2009-01-01), pages 95 - 101, XP055200008, Retrieved from the Internet <URL:http://www.european-poultry-science.com/Artikel.dll/m08-36mk_NDIxOTA1NA.PDF?UID=767931A8AEF51C7E3043F100D4782B1C6D88D0A88ED984A9> [retrieved on 20150703] *
KONG WEIJIA ET AL: "Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 12, 1 December 2004 (2004-12-01), pages 1344 - 1351, XP002465824, ISSN: 1078-8956, DOI: 10.1038/NM1135 *
KOZAK W ET AL: "Attenuation of lipopolysaccharide fever in rats by protein kinase C inhibitors", AMERICAN JOURNAL OF PHYSIOLOGY, BETHESDA, MD : AMERICAN PHYSIOLOGICAL SOCIETY, 1898-BALTIMORE, MD. [U.A.] : AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 273, no. 3 pt.2, 1 September 1997 (1997-09-01), pages R873 - R879, XP009182867, ISSN: 0002-9513 *
MORGAN B FARNELL ET AL: "Differential Activation of Signal Transduction Pathways Mediating Oxidative Burst by Chicken Heterophils in Response to Stimulation with Lipopolysaccharide and Lipoteichoic Acid", 15 INFLAMMATION, 1 August 2003 (2003-08-01), XP055200294, Retrieved from the Internet <URL:http://download.springer.com/static/pdf/498/art%3A10.1023%2FA%3A1025088514676.pdf?originUrl=http://link.springer.com/article/10.1023/A:1025088514676&token2=exp=1436183404~acl=/static/pdf/498/art%253A10.1023%252FA%253A1025088514676.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1023%2FA%> [retrieved on 20150706] *
NIU XIAOFENG ET AL: "Protective effect of sanguinarine against acetic acid-induced ulcerative colitis in mice", TOXICOLOGY AND APPLIED PHARMACOLOGY, ACADEMIC PRESS, AMSTERDAM, NL, vol. 267, no. 3, 23 January 2013 (2013-01-23), pages 256 - 265, XP028982848, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2013.01.009 *
S. REAGAN-SHAW: "Enhancement of UVB radiation-mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 2, 1 February 2006 (2006-02-01), pages 418 - 429, XP055200330, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-05-0250 *
SHENGLI XUEBAO, vol. 55, no. 3, 25 June 2003 (2003-06-25), pages 265 - 272, ISSN: 0371-0874 *
TANAKA S ET AL: "INFLUENCE OF NATURAL AND SYNTHETIC COMPOUNDS ON CELL SURFACE EXPRESSION OF CELL ADHESION MOLECULES, ICAM-1 AND VCAM-1", PLANTA MEDICA, THIEME VERLAG, DE, vol. 67, no. 2, 1 January 2001 (2001-01-01), pages 108 - 113, XP009003131, ISSN: 0032-0943, DOI: 10.1055/S-2001-11514 *
VIVEK MISHRA ET AL: "Edible oil adulterants, argemone oil and butter yellow, as aetiological factors for gall bladder cancer", EUROPEAN JOURNAL OF CANCER, vol. 48, no. 13, 1 September 2012 (2012-09-01), pages 2075 - 2085, XP055200340, ISSN: 0959-8049, DOI: 10.1016/j.ejca.2011.09.026 *
WEIFENG LI ET AL: "Effect of Chelerythrine Against Endotoxic Shock in Mice and Its Modulation of Inflammatory Mediators in Peritoneal Macrophages Through the Modulation of Mitogen-Activated Protein Kinase (MAPK) Pathway", INFLAMMATION, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 35, no. 6, 24 July 2012 (2012-07-24), pages 1814 - 1824, XP035144007, ISSN: 1573-2576, DOI: 10.1007/S10753-012-9502-1 *
XIAOFENG NIU ET AL: "The anti-inflammatory effects of sanguinarine and its modulation of inflammatory mediators from peritoneal macrophages", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 689, no. 1, 24 May 2012 (2012-05-24), pages 262 - 269, XP028433355, ISSN: 0014-2999, [retrieved on 20120613], DOI: 10.1016/J.EJPHAR.2012.05.039 *

Also Published As

Publication number Publication date
AT515336A1 (de) 2015-08-15
WO2015114163A2 (de) 2015-08-06

Similar Documents

Publication Publication Date Title
EP3526305A4 (de) Faserkonfigurationen für bohrlochbehandlungszusammensetzungen
EP3261640A4 (de) 5ht-agonisten zur behandlung von erkrankungen
AU2018242623B2 (en) Compounds and compositions for treating hematological disorders
WO2016011390A8 (en) Irak4 inhibiting agents
PL3121175T3 (pl) Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2
EP3254106A4 (de) Verfahren und zusammensetzungen zur diagnose von hirnläsionen oder nervendegeneration
EP3538189A4 (de) Zusammensetzungen, vorrichtungen und verfahren zur behandlung von opioidrezeptorvermittelten zuständen
IL252089A0 (en) 2-amino-6-(difluoromethyl)-5,5,-difluoro-6-phenyl-6,5,4,3-tetrahydropyridines as BACE1 inhibitors
EP3142664A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von augenerkrankungen
ZA201902111B (en) Substituted pyrido[3,4¿b]indoles for the treatment of cartilage disorders
IL276513A (en) Quinolone analogs and their salts, preparations and method of using them
EP3310353A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von augenerkrankungen
WO2015114163A3 (de) Zusammensetzung zur prophylaxe oder behandlung von oxidativem stress
EP3262065A4 (de) Verfahren und zusammensetzungen zur behandlung von dystroglycanopathieerkrankungen
HK1257997A1 (zh) β受体阻滞剂的S-对映体富集组合物用於治疗肌肉无力
WO2017059401A3 (en) Androgen receptor ligands
EP3507277B8 (de) Hydroxynorketaminderivate zur behandlung von erkrankungen
EP3565556A4 (de) Morphinanderivate und zusammensetzungen damit zur behandlung von autoimmun-, entzündungs- oder infektionserkrankungen
HK40104383A (zh) 用於治疗血液病的化合物和组合物
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
HK40016519A (en) Composition for treating or preventing climacteric disorders
TWI907333B (zh) 用於治療cns病症之組合物及方法
HK40041169A (en) Compositions and methods for treating or preventing vasomotor symptoms
WO2015120334A3 (en) Compositions and methods for treating neurological disorders
HK40052564A (en) Compositions and methods for treating the eye

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15702277

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15702277

Country of ref document: EP

Kind code of ref document: A2